tiprankstipranks
Trending News
More News >

Corbus says first patient dosed in PD-1 combo arm of Phase 1 study of CRB-701

Corbus Pharmaceuticals (CRBP) announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors. Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda. The three-part Phase 1 study is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses and is followed by Part B and Part C. The Company expects to provide a data update and establish the recommended Phase 2 dose in the fourth quarter of this year.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1